Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$1.17
+1.8%
$0.99
$0.69
$3.94
$232.09M0.74.83 million shs2.32 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$3.96
+3.4%
$3.85
$1.92
$11.60
$208.93M2.28346,421 shs311,539 shs
ProKidney Corp. stock logo
PROK
ProKidney
$0.69
+19.1%
$0.77
$0.46
$2.59
$201.67M1.26702,060 shs1.54 million shs
Renovaro Inc. stock logo
RENB
Renovaro
$0.28
-0.5%
$0.32
$0.27
$2.10
$47.85M0.511.57 million shs622,484 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
0.00%+17.85%-4.02%-2.42%-52.20%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
0.00%+7.03%-6.16%+81.65%+68.51%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%+3.04%-29.52%+16.37%-69.38%
Renovaro Inc. stock logo
RENB
Renovaro
0.00%-5.02%-10.00%-35.94%-82.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
4.2201 of 5 stars
3.43.00.03.92.61.70.6
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
4.1337 of 5 stars
3.04.00.04.61.13.30.0
ProKidney Corp. stock logo
PROK
ProKidney
1.7933 of 5 stars
3.00.00.00.01.14.20.6
Renovaro Inc. stock logo
RENB
Renovaro
1.1238 of 5 stars
0.02.00.00.02.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00497.78% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.00
Hold$9.00127.27% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.00
Hold$3.50407.98% Upside
Renovaro Inc. stock logo
RENB
Renovaro
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RENB, ESPR, PROK, and KOD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
ProKidney Corp. stock logo
PROK
ProKidney
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00 ➝ $1.00
6/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/7/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.00
4/8/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M0.70$0.02 per share48.70($1.97) per share-0.59
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.86 per shareN/A
ProKidney Corp. stock logo
PROK
ProKidney
$80K2,520.88N/AN/A($3.41) per share-0.20
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/A$0.89 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.80N/AN/AN/A-59.03%-0.91%-29.47%8/11/2025 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)
ProKidney Corp. stock logo
PROK
ProKidney
-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)
Renovaro Inc. stock logo
RENB
Renovaro
-$88.43M-$0.77N/AN/AN/A-60.38%-47.04%N/A

Latest RENB, ESPR, PROK, and KOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.89-$1.09-$0.20-$1.09N/AN/A
5/12/2025Q1 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.16-$0.13+$0.03-$0.13N/A$0.23 million
5/6/2025Q1 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.18
0.81
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
4.62
4.62
ProKidney Corp. stock logo
PROK
ProKidney
N/A
10.96
10.96
Renovaro Inc. stock logo
RENB
Renovaro
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
Renovaro Inc. stock logo
RENB
Renovaro
71.41%

Insider Ownership

CompanyInsider Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.70%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
45.90%
ProKidney Corp. stock logo
PROK
ProKidney
41.49%
Renovaro Inc. stock logo
RENB
Renovaro
21.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.20 million194.83 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9052.76 million28.55 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
3292.70 million171.26 millionOptionable
Renovaro Inc. stock logo
RENB
Renovaro
20172.12 million134.74 millionOptionable

Recent News About These Companies

Renovaro (NASDAQ:RENB) Stock Price Down 1.3% - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$1.17 +0.02 (+1.83%)
Closing price 07/3/2025 03:42 PM Eastern
Extended Trading
$1.16 -0.01 (-0.51%)
As of 07/3/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$3.96 +0.13 (+3.39%)
Closing price 07/3/2025 03:35 PM Eastern
Extended Trading
$3.89 -0.07 (-1.87%)
As of 07/3/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

ProKidney stock logo

ProKidney NASDAQ:PROK

$0.69 +0.11 (+19.06%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$0.69 0.00 (-0.44%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Renovaro stock logo

Renovaro NASDAQ:RENB

$0.28 0.00 (-0.47%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$0.29 +0.01 (+3.96%)
As of 07/3/2025 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.